REGENXBIO Inc. (RGNX) Financial Ratios
12 years of historical data (2013–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 6.94
30Y Low6.9·High15.9
P/FCF
N/A
—
5yr avg: 10.66
30Y Low10.7·High16.8
P/B Ratio
↓
1.99
↓-19% vs avg
5yr avg: 2.45
30Y Low0.7·High5.4
ROE
↓
-79.5%
↑-108% vs avg
5yr avg: -38.3%
30Y Low-79%·High29%
Debt/EBITDA
N/A
—
5yr avg: 0.51
30Y Low0.1·High0.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RGNX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
REGENXBIO Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $527M | $383M | $785M | $979M | $1.4B | $1.7B | $1.5B | $1.5B | $993M | $490M | $152M |
| Enterprise Value | $552M | $407M | $840M | $977M | $1.2B | $1.4B | $1.4B | $1.5B | $947M | $465M | $98M |
| P/E Ratio → | -2.27 | — | — | — | 11.24 | — | — | 15.37 | — | — | — |
| P/S Ratio | 6.33 | 4.59 | 8.70 | 8.68 | 3.05 | 10.94 | 42.66 | 7.04 | 95.59 | 106.75 | 20.07 |
| P/B Ratio | 1.99 | 1.47 | 2.52 | 1.90 | 1.88 | 4.48 | 3.34 | 3.02 | 5.43 | 3.03 | 0.70 |
| P/FCF | — | — | — | — | 10.66 | — | — | 16.83 | — | — | — |
| P/OCF | — | — | — | — | 6.56 | — | — | 14.69 | — | — | — |
P/E links to full P/E history page with 30-year chart
RGNX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.89 | 9.31 | 8.66 | 2.50 | 9.22 | 41.01 | 6.72 | 91.10 | 101.34 | 12.94 |
| EV / EBITDA | — | — | — | — | 6.94 | — | — | 15.94 | — | — | — |
| EV / EBIT | — | — | — | — | 7.36 | — | — | 16.66 | — | — | — |
| EV / FCF | — | — | — | — | 8.74 | — | — | 16.06 | — | — | — |
RGNX Profitability
Margins and return-on-capital ratios measuring operating efficiency
REGENXBIO Inc. earns an operating margin of -280.0%. Operating margins have compressed from -233.2% to -280.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -79.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.7% | 59.7% | 58.8% | 51.6% | 89.0% | 76.9% | 76.6% | 95.6% | 83.6% | 79.1% | 80.2% |
| Operating Margin | -280.0% | -280.0% | -297.1% | -233.2% | 34.0% | -77.1% | -422.9% | 40.3% | -730.2% | -1423.8% | -304.9% |
| Net Profit Margin | -272.5% | -272.5% | -292.0% | -248.7% | 27.2% | -72.0% | -268.9% | 45.7% | -704.0% | -1372.1% | -300.6% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -79.5% | -79.5% | -63.7% | -43.8% | 22.4% | -26.9% | -19.8% | 28.9% | -42.4% | -33.3% | -21.6% |
| ROA | -43.7% | -43.7% | -37.4% | -28.8% | 14.0% | -18.4% | -18.2% | 26.9% | -39.4% | -32.0% | -20.3% |
| ROIC | -53.8% | -53.8% | -45.7% | -38.7% | 38.8% | -35.5% | -26.9% | 23.0% | -41.7% | -32.7% | -21.9% |
| ROCE | -57.9% | -57.9% | -46.8% | -31.2% | 19.9% | -21.9% | -30.2% | 25.0% | -43.7% | -34.4% | -21.9% |
RGNX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $25M ($82M total debt minus $58M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.32 | 0.32 | 0.29 | 0.18 | 0.11 | 0.19 | 0.03 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | 0.51 | — | — | 0.06 | — | — | — |
| Net Debt / Equity | — | 0.09 | 0.18 | -0.00 | -0.34 | -0.70 | -0.13 | -0.14 | -0.25 | -0.15 | -0.25 |
| Net Debt / EBITDA | — | — | — | — | -1.52 | — | — | -0.76 | — | — | — |
| Debt / FCF | — | — | — | — | -1.92 | — | — | -0.76 | — | — | — |
| Interest Coverage | -18.43 | -18.43 | -39.07 | -11.30 | 6.09 | -154.65 | — | — | — | — | -1156.85 |
RGNX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
REGENXBIO Inc.'s current ratio of 2.69x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.19x to 2.69x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.69 | 2.69 | 2.57 | 3.19 | 3.98 | 6.52 | 10.25 | 15.24 | 11.64 | 9.66 | 27.23 |
| Quick Ratio | 2.69 | 2.69 | 2.57 | 3.19 | 3.98 | 6.39 | 10.25 | 14.98 | 11.27 | 9.47 | 26.99 |
| Cash Ratio | 2.27 | 2.27 | 2.11 | 2.80 | 3.51 | 5.84 | 8.80 | 14.42 | 11.14 | 9.26 | 26.31 |
| Asset Turnover | — | 0.18 | 0.16 | 0.14 | 0.42 | 0.22 | 0.07 | 0.40 | 0.05 | 0.03 | 0.03 |
| Inventory Turnover | 3.40 | — | — | — | — | 3.40 | — | 1.68 | 0.32 | 0.54 | 1.47 |
| Days Sales Outstanding | — | 94.47 | 106.54 | 98.09 | 25.17 | 101.54 | 395.20 | 14.34 | 16.61 | 82.08 | 102.75 |
RGNX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
REGENXBIO Inc. returns 0.2% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 8.9% | — | — | 6.5% | — | — | — |
| FCF Yield | — | — | — | — | 9.4% | — | — | 5.9% | — | — | — |
| Buyback Yield | 0.2% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.2% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $50M | $44M | $43M | $44M | $37M | $37M | $37M | $30M | $26M | $9M |
Peer Comparison
Compare RGNX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RGNXYou | $527M | -2.3 | — | — | 59.7% | -280.0% | -79.5% | -53.8% | — |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See RGNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RGNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RGNX vs SGMO
Side-by-side business, growth, and profitability comparison vs Sangamo Therapeutics, Inc..
Start ComparisonRGNX — Frequently Asked Questions
Quick answers to the most common questions about buying RGNX stock.
What is REGENXBIO Inc.'s P/E ratio?
REGENXBIO Inc.'s current P/E ratio is -2.3x. The historical average is 13.3x.
What is REGENXBIO Inc.'s ROE?
REGENXBIO Inc.'s return on equity (ROE) is -79.5%. The historical average is -28.0%.
Is RGNX stock overvalued?
Based on historical data, REGENXBIO Inc. is trading at a P/E of -2.3x. Compare with industry peers and growth rates for a complete picture.
What are REGENXBIO Inc.'s profit margins?
REGENXBIO Inc. has 59.7% gross margin and -280.0% operating margin.